Chimerix to Present at Cantor Fitzgerald Global Healthcare Conference
A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and compound library have produced brincidofovir (BCV, CMX001), currently being evaluated in the AdAPT trial for the treatment of adenovirus in pediatric transplant recipients; CMX157, which was licensed to ContraVir Pharmaceuticals; and CMX521, the first clinical-stage direct-acting antiviral for the treatment and prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT:
Investor Relations:
919 972-7115
ir@chimerix.com
or
Will O’Connor
Stern Investor Relations
will@sternir.com
212-362-1200
Media:
lmasonson@w2group.com
917 459-6164
Source: Chimerix, Inc.